[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Inti Labs\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":71},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100557955","trial-to-evaluate-the-clinical-utility-of-non-invasive-endometrial-receptivity-test-ora-in-patients-with-implantation-failure-100557955",false,"NCT06544837","Trial to Evaluate the Clinical Utility of Non-invasive Endometrial Receptivity Test (Ora) in Patients With Implantation Failure","Multi-national, Multi-center, Randomized Controlled Trial to Evaluate the Clinical Utility of Non-invasive Endometrial Receptivity Test (Ora) in Patients With Implantation Failure","Inclusion Criteria:\n\n* Experienced implantation failure with euploid or low-level mosaic (\\\u003C 30%) embryos in the past two years.\n* Female age 28-45 years.\n* Consent to undergo a simulated cycle for non-invasive optimal implantation window testing.\n* Plan to undergo a frozen embryo transfer cycle.\n* Have at least one euploid or low-level mosaic (\\\u003C 30%) frozen blastocyst.\n\nExclusion Criteria:\n\n* Presence of uterine cavity abnormalities that may affect implantation, such as polyps, fibroids ≧4 cm, or hydrosalpinx\n* Presence of systemic diseases that may affect reproductive techniques (e.g., autoimmune diseases)\n* Body mass index (BMI) over 30 kg\u002Fm²","FEMALE","28 Years","45 Years",{"count":20,"type":21},1000,"ESTIMATED","INTERVENTIONAL",[24],"NA","The adjustment of the timing of embryo transfer based on the endometrial receptivity profile and transferring embryo(s) of good quality with normal chromosomes (diagnosed by Preimplantation Genetic Testing for Aneuploidy, PGT-A) are the two main causes to improve the success of assisted reproduction treatments (ART). Previously, endometrial receptivity analysis was performed on women undergoing IVF treatment through an invasive endometrial tissue biopsy. The aim of this study is to determine the clinical benefits of ORA, a novel non-invasive endometrial receptivity test that determines the optimal time for embryo transfer through a blood draw instead of an invasive endometrial tissue biopsy. It is expected to recruit 1000 couples whose embryos will be analyzed by PGT-A and\u002For who are going to evaluate their endometrium expression profile for endometrial receptivity. The patients will be randomized into two groups, (1) Control group : undergoing PGT-A only; (2) Study group : the undergoing both PGT-A and ORA. ART will be performed based on the results of PGT-A and\u002For ORA. Reproductive success, such as implantation rates (IR), pregnancy rates (PR), ongoing pregnancy rates (OGP) and live birth rates (LBR) will be tracked and compared.\n\nPreliminary results demonstrate that both PGT-A and ORA can contribute to reproductive success, improving implantation rates in patients with implantation failure. Our hypothesis suggests that PGT-A and ORA could improve the performance of ART in infertile patients.",[27,28,29,30,31,32],"IVF","Window of Implantation","microRNA","Implantation","Non-invasive Testing","Endometrial Receptivity","RECRUITING","2025-05-04",{"date":36,"type":37},"2025-05-07","ACTUAL",{"date":39,"type":37},"2024-06-22",{"date":41,"type":21},"2027-06-01",{"name":43,"class":44},"Inti Labs","INDUSTRY",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":16,"minAge":4,"maxAge":53,"enrollmentInfo":54,"targetDuration":56,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":45},"100580607","to-investigate-the-relationship-between-the-viscoelastic-properties-of-the-zona-pellucida-of-human-oocyte-and-the-blastocyst-utilization-rate-100580607","NCT06839495","To Investigate the Relationship Between the Viscoelastic Properties of the Zona Pellucida of Human Oocyte and the Blastocyst Utilization Rate","Inclusion Criteria:\n\n1. Women who have started the in vitro fertilization (IVF) treatment and related examinations.\n2. Female participants aged ≤38 years with an anti-Müllerian hormone (AMH) concentration greater than 1.1 ng\u002FmL and a collected oocyte count of more than 10.\n3. Participants who consent to undergoing IVF with intracytoplasmic sperm injection (ICSI) and time-lapse embryo culture.\n\nExclusion Criteria:\n\n1. Women diagnosed with untreated uterine abnormalities as assessed by a physician.\n2. Participants with a body mass index (BMI) outside the range of 18.5-30 kg\u002Fm\\^2.\n3. Patients undergoing IVF using sperm retrieved through surgical extraction.\n4. Patients undergoing IVF using donated oocytes or donated sperm.",true,"38 Years",{"count":55,"type":21},200,"1 Year","OBSERVATIONAL","In in vitro fertilization (IVF) treatment, oocyte quality is one of the key factors influencing the success rate of fertilization. The zona pellucida (ZP) is a spherical structure that surrounds the human oocyte and, together with cumulus cells, forms the cumulus-oocyte complex (COC). These two components engage in bidirectional communication and metabolic regulation to support oocyte growth and maturation. Additionally, the physical rigidity of the zona pellucida plays an important role in the fertilization process.\n\nOPAL X1 is a non-invasive and highly safe device specifically designed to measure the viscoelastic properties of the zona pellucida. This system consists of an ultra-precise pressure control mechanism and analytical software to assess oocyte quality before fertilization. OPAL X1 applies pressure through a micropipette while simultaneously recording the movement of the zona pellucida within the micropipette. An algorithm then analyzes the recorded motion images and classifies the oocytes into different quality grades (Grade A, B, C).\n\nThis study aims to investigate the correlation between oocyte classification results obtained from the OPAL X1 grading system and oocyte quality. By integrating spindle-view and time-lapse technology, the study seeks to identify the optimal parameters for oocyte quality assessment. Furthermore, these findings will be applied to predict the success rate of intracytoplasmic sperm injection (ICSI), the likelihood of blastocyst formation, and pregnancy outcomes after embryo transfer. Ultimately, this study aims to provide more efficient and timely embryo development information before IVF, assisting clinicians in formulating and optimizing IVF treatment strategies.",[60,61,62],"Oocyte","Zona Pellucida","Viscoelastic Property","2025-02-19",{"date":65,"type":37},"2025-02-21",{"date":67,"type":37},"2024-07-31",{"date":69,"type":21},"2025-12-31",{"name":43,"class":44},""]